Log In
Print
BCIQ
Print
Print this Print this
 

tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionCo-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor, plus elvitegravir/cobicistat/emtricitabine
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection in treatment-naive adults
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today